1762 related articles for article (PubMed ID: 15748904)
41. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
42. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
Brockhoff G; Heckel B; Schmidt-Bruecken E; Plander M; Hofstaedter F; Vollmann A; Diermeier S
Cell Prolif; 2007 Aug; 40(4):488-507. PubMed ID: 17635517
[TBL] [Abstract][Full Text] [Related]
43. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
44. The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein.
Li H; Sánchez-Torres J; Del Carpio A; Salas V; Villalobo A
Biochem J; 2004 Jul; 381(Pt 1):257-66. PubMed ID: 15080792
[TBL] [Abstract][Full Text] [Related]
45. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
46. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
47. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?
Arteaga CL
J Clin Oncol; 2006 Aug; 24(23):3722-5. PubMed ID: 16847283
[No Abstract] [Full Text] [Related]
48. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
49. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
50. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.
Ciravolo V; Huber V; Ghedini GC; Venturelli E; Bianchi F; Campiglio M; Morelli D; Villa A; Della Mina P; Menard S; Filipazzi P; Rivoltini L; Tagliabue E; Pupa SM
J Cell Physiol; 2012 Feb; 227(2):658-67. PubMed ID: 21465472
[TBL] [Abstract][Full Text] [Related]
51. A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines.
Blackburn E; Zona S; Murphy ML; Brown IR; Chan SK; Gullick WJ
Breast Cancer Res Treat; 2012 Jul; 134(1):53-9. PubMed ID: 22169894
[TBL] [Abstract][Full Text] [Related]
52. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
53. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
54. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
[TBL] [Abstract][Full Text] [Related]
55. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
[TBL] [Abstract][Full Text] [Related]
56. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.
Longva KE; Pedersen NM; Haslekås C; Stang E; Madshus IH
Int J Cancer; 2005 Sep; 116(3):359-67. PubMed ID: 15800944
[TBL] [Abstract][Full Text] [Related]
57. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
58. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
Camirand A; Lu Y; Pollak M
Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030
[TBL] [Abstract][Full Text] [Related]
59. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
Fischgräbe J; Götte M; Michels K; Kiesel L; Wülfing P
Int J Cancer; 2010 Aug; 127(3):696-706. PubMed ID: 19960438
[TBL] [Abstract][Full Text] [Related]
60. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]